New nasal spray aims to tame severe asthma Flare-Ups
NCT ID NCT07250594
Summary
This study is testing a new nasal spray called AD17002 for adults with a specific type of severe asthma that is not well managed by their current medications. The goal is to see if adding this spray to existing treatments is safe and can help reduce the frequency and severity of asthma attacks. About 126 participants will use the spray or a placebo for three months to compare results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advagene Biopharma
Taipei, Taiwan, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.